Christopher S. Boerner insider trades

Open-market stock purchases and sales by Christopher S. Boerner, Director at Colgate Palmolive Co, from SEC Form 4 filings since Aug 19, 2011.

Track record: 100% of 3 scored buys are up 5% or more since purchase, averaging +25%.

Recent trades

DateStockTradeValue
May 11, 2026CL Colgate Palmolive CoBought (not open market)—
May 11, 2026CL Colgate Palmolive CoBought (not open market)—
Mar 10, 2026BMY Bristol Myers Squibb CoSold (not open market)—
Mar 10, 2026BMY Bristol Myers Squibb CoSold (not open market)$181K
Mar 10, 2026BMY Bristol Myers Squibb CoSold (not open market)—
Mar 10, 2026BMY Bristol Myers Squibb CoSold (not open market)$185K
Mar 10, 2026BMY Bristol Myers Squibb CoSold (not open market)—
Mar 10, 2026BMY Bristol Myers Squibb CoSold (not open market)$632K
Mar 10, 2026BMY Bristol Myers Squibb CoSold (not open market)—
Mar 10, 2026BMY Bristol Myers Squibb CoSold (not open market)$279K
Mar 10, 2026BMY Bristol Myers Squibb CoBought (not open market)—
Mar 10, 2026BMY Bristol Myers Squibb CoBought (not open market)—
Mar 10, 2026BMY Bristol Myers Squibb CoBought (not open market)—
Mar 10, 2026BMY Bristol Myers Squibb CoBought (not open market)—
Mar 10, 2026BMY Bristol Myers Squibb CoBought (not open market)—
Mar 10, 2026BMY Bristol Myers Squibb CoBought (not open market)—
Nov 1, 2025BMY Bristol Myers Squibb CoSold (not open market)—
Nov 1, 2025BMY Bristol Myers Squibb CoSold (not open market)$57K
Nov 1, 2025BMY Bristol Myers Squibb CoBought (not open market)—

Companies traded

  • CL Colgate Palmolive Co: other filings, last May 11, 2026
  • BMY Bristol Myers Squibb Co: 3 buys, 1 sale, last Mar 10, 2026
  • SGEN Seattle Genetics Inc /WA: 4 sales, last Aug 26, 2014
  • AKAO Achaogen Inc: other filings, last Mar 27, 2014

Get free alerts when Christopher S. Boerner files a new trade →